Clinical Trial Update: Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of nintedanib and docetaxel in Japanese patients with the adenocarcinoma subtype of non-small cell lung cancer afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2018-08-06